Loading...
XSHE
002581
Market cap314mUSD
Jul 10, Last price  
3.30CNY
1D
2.17%
1Q
-55.35%
Jan 2017
-86.40%
IPO
-59.53%
Name

Shandong Sinobioway Biomedicine Co Ltd

Chart & Performance

D1W1MN
XSHE:002581 chart
P/E
P/S
7.92
EPS
Div Yield, %
Shrs. gr., 5y
0.04%
Rev. gr., 5y
-7.36%
Revenues
275m
-23.75%
177,251,964213,798,562247,173,208246,369,291287,525,771401,067,940624,318,646858,285,7221,264,879,4351,162,416,642664,593,783567,637,225276,830,416402,713,045402,713,044357,080,537357,080,536429,790,104360,405,013274,810,013
Net income
-116m
L-15.32%
37,042,78058,823,81570,255,75566,976,25073,783,828109,383,711225,009,315250,253,852417,695,148388,411,595-103,752,52863,383,510-195,934,410271,001,671271,001,6710-14,680,301-332,458,284-137,313,570-116,283,662
CFO
-254m
L+3,775.50%
25,067,69546,888,20754,056,99585,712,12374,426,51563,035,34383,132,88380,108,148137,728,784169,315,097271,106,65574,456,07548,414,58118,510,199-46,015,293-54,485,087-36,506,208-6,547,055-253,731,396
Dividend
Jun 21, 20160.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Sinobioway Biomedicine Co., Ltd., headquartered in Zibo, China, is a key producer and supplier of various chemical compounds, including trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, and ethyl formate. The company also manufactures general nerve growth factor and alfaron. Its pharmaceutical offerings further encompass NOBEX, which is a murine nerve growth factor delivered via injection; Anferon, a human recombinant interferon alpha 2b injection; and Jaferon, a human recombinant interferon alpha 2b formulated as a spray. Beyond these, the company provides a diverse portfolio of vaccines such as Healive, an inactivated vaccine for hepatitis A; Bilive, a combined vaccine targeting both hepatitis A and B; Panflu, designed for pandemic influenza; Anflu, a preservative-free influenza virus vaccine; and Panflu.1, specifically for Type A H1N1 influenza, among other related products. Established in 2000, its market extends internationally, with products being exported to roughly 20 nations and territories across Europe and the United States.
IPO date
May 20, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT